Theratechnologies Inc
TSX:TH

Watchlist Manager
Theratechnologies Inc Logo
Theratechnologies Inc
TSX:TH
Watchlist
Price: 4.47 CAD -4.89% Market Closed
Market Cap: 205.5m CAD

Operating Margin
Theratechnologies Inc

10.1%
Current
-19%
Average
-4.9%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
10.1%
=
Operating Profit
8.5m
/
Revenue
84.4m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
CA
Theratechnologies Inc
TSX:TH
205.5m CAD
10%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
413.6B USD
33%
US
Amgen Inc
NASDAQ:AMGN
183.9B USD
34%
US
Gilead Sciences Inc
NASDAQ:GILD
156.4B USD
39%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
110.6B USD
39%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
75.1B USD
28%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
60.6B USD
-7%
AU
CSL Ltd
ASX:CSL
87.2B AUD
26%
NL
argenx SE
XBRU:ARGX
48.8B EUR
22%
No Stocks Found

Theratechnologies Inc
Glance View

Market Cap
205.5m CAD
Industry
Biotechnology

Theratechnologies, Inc. is a pharmaceutical company. The company is headquartered in Montreal, Quebec and currently employs 87 full-time employees. The firm has two approved products: EGRIFTA SV in the United States, and Trogarzo in the United States, the European Union and the United Kingdom. EGRIFTA SV (tesamorelin for injection) is developed for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy. Trogarzo (ibalizumab-uiyk) is developed for HIV treatment. The treatment is infused every two weeks. The company is a new class of antiretrovirals (ARV), and is a long-acting ARV therapy that can lead to an undetectable viral load in combination with other ARVs. The firm markets its prescription products in the United States, Europe and Canada. Its research pipeline is focused on specialized therapies addressing unmet medical needs in HIV, oncology and non-alcoholic steatohepatitis (NASH).

TH Intrinsic Value
5.4 CAD
Undervaluation 17%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
10.1%
=
Operating Profit
8.5m
/
Revenue
84.4m
What is the Operating Margin of Theratechnologies Inc?

Based on Theratechnologies Inc's most recent financial statements, the company has Operating Margin of 10.1%.

Back to Top